$TOI
Oncology Institute, Inc.

2023 Q2 Form 10-Q Financial Statement

#000162828023017229 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $80.22M $76.19M
YoY Change 31.69% 38.13%
Cost Of Revenue $65.11M $62.09M
YoY Change 30.79% 44.95%
Gross Profit $15.12M $14.10M
YoY Change 35.68% 14.42%
Gross Profit Margin 18.84% 18.5%
Selling, General & Admin $28.73M $28.83M
YoY Change 1.33% -3.27%
% of Gross Profit 190.02% 204.48%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $601.0K $1.269M
YoY Change -45.26% 28.57%
% of Gross Profit 3.98% 9.0%
Operating Expenses $28.73M $28.83M
YoY Change -2.45% -3.27%
Operating Profit -$14.94M -$32.87M
YoY Change -18.39% 77.94%
Interest Expense -$1.638M -$1.443M
YoY Change 2585.25% -2050.0%
% of Operating Profit
Other Income/Expense, Net -$1.860M $2.913M
YoY Change -114.44% -92.32%
Pretax Income -$16.80M -$29.95M
YoY Change 206.25% -253.88%
Income Tax $99.00K $44.00K
% Of Pretax Income
Net Earnings -$16.90M -$30.00M
YoY Change 209.87% -255.54%
Net Earnings / Revenue -21.06% -39.37%
Basic Earnings Per Share -$0.19 -$0.33
Diluted Earnings Per Share -$0.19 -$0.33
COMMON SHARES
Basic Shares Outstanding 75.35M shares 74.55M shares
Diluted Shares Outstanding 74.12M shares 73.45M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.18M $55.38M
YoY Change -38.97% -41.49%
Cash & Equivalents $28.89M $15.25M
Short-Term Investments $10.29M $40.13M
Other Short-Term Assets $5.827M $6.942M
YoY Change -42.01% -40.25%
Inventory $12.17M $10.25M
Prepaid Expenses $5.827M $6.942M
Receivables $46.39M $45.96M
Other Receivables $499.0K $428.0K
Total Short-Term Assets $104.1M $119.0M
YoY Change -7.25% -14.93%
LONG-TERM ASSETS
Property, Plant & Equipment $10.77M $9.846M
YoY Change -53.71% 100.57%
Goodwill $7.230M $4.551M
YoY Change -82.91%
Intangibles $19.34M $17.23M
YoY Change -1.96%
Long-Term Investments $58.94M $58.84M
YoY Change
Other Assets $557.0K $527.0K
YoY Change 36.86% 58.73%
Total Long-Term Assets $125.9M $115.7M
YoY Change 62.36% 73.49%
TOTAL ASSETS
Total Short-Term Assets $104.1M $119.0M
Total Long-Term Assets $125.9M $115.7M
Total Assets $230.0M $234.6M
YoY Change 21.2% 13.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.12M $11.95M
YoY Change -5.59% -5.16%
Accrued Expenses $14.13M $12.25M
YoY Change -18.48% -15.64%
Deferred Revenue $610.0K $875.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.51M $30.09M
YoY Change -7.26% -4.56%
LONG-TERM LIABILITIES
Long-Term Debt $83.69M $82.14M
YoY Change
Other Long-Term Liabilities $553.0K $765.0K
YoY Change -98.1% -79.87%
Total Long-Term Liabilities $84.24M $82.91M
YoY Change 189.22% 2081.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.51M $30.09M
Total Long-Term Liabilities $84.24M $82.91M
Total Liabilities $145.2M $136.2M
YoY Change 120.87% 82.82%
SHAREHOLDERS EQUITY
Retained Earnings -$110.0M -$93.08M
YoY Change 111.8%
Common Stock $7.000K $7.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $84.72M $98.41M
YoY Change
Total Liabilities & Shareholders Equity $230.0M $234.6M
YoY Change 21.2% 13.62%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$16.90M -$30.00M
YoY Change 209.87% -255.54%
Depreciation, Depletion And Amortization $601.0K $1.269M
YoY Change -45.26% 28.57%
Cash From Operating Activities -$8.660M -$15.45M
YoY Change -16.56% -9.0%
INVESTING ACTIVITIES
Capital Expenditures $937.0K $1.839M
YoY Change -169.82% 83.53%
Acquisitions
YoY Change
Other Investing Activities $25.84M $20.24M
YoY Change -389.69%
Cash From Investing Activities $24.90M $18.40M
YoY Change -342.67% -1936.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.601M -$1.709M
YoY Change -75.66% 3.14%
NET CHANGE
Cash From Operating Activities -8.660M -$15.45M
Cash From Investing Activities 24.90M $18.40M
Cash From Financing Activities -2.601M -$1.709M
Net Change In Cash 13.64M $1.240M
YoY Change -143.55% -106.31%
FREE CASH FLOW
Cash From Operating Activities -$8.660M -$15.45M
Capital Expenditures $937.0K $1.839M
Free Cash Flow -$9.597M -$17.29M
YoY Change 6.2% -3.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001799191
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39248
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
The Oncology Institute, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3562323
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
18000 Studebaker Rd, Suite 800
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cerritos
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90703
CY2023Q1 dei City Area Code
CityAreaCode
562
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
735-3226
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
75351310 shares
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15250000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14010000 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
40132000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
59796000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
45956000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39816000 usd
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
428000 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
617000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
10254000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9261000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6942000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6918000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
118962000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
130418000 usd
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
58841000 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
58354000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9846000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8547000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24678000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24494000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17228000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17957000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
4551000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
21418000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
527000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
477000 usd
CY2023Q1 us-gaap Assets
Assets
234633000 usd
CY2022Q4 us-gaap Assets
Assets
261665000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
11946000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9372000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5639000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5498000 usd
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
255000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
255000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12245000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14595000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
30085000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29720000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22251000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22060000 usd
CY2023Q1 toi Derivative Warrant Liabilities Noncurrent
DerivativeWarrantLiabilitiesNoncurrent
207000 usd
CY2022Q4 toi Derivative Warrant Liabilities Noncurrent
DerivativeWarrantLiabilitiesNoncurrent
350000 usd
CY2023Q1 toi Derivative Earnout Liabilities
DerivativeEarnoutLiabilities
51000 usd
CY2022Q4 toi Derivative Earnout Liabilities
DerivativeEarnoutLiabilities
803000 usd
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
642000 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3960000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
82144000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
80621000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
765000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
868000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
82000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
108000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
136227000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
138490000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73754609 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73754609 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73265621 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73265621 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
7000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
165045 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
165045 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
165045 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
165045 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
191479000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
186250000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93080000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63082000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
98406000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
123175000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234633000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261665000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
76192000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55161000 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
16867000 usd
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28830000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29806000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1269000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
987000 usd
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
109059000 usd
CY2022Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
73632000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32867000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18471000 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2650000 usd
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-74000 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
1207000 usd
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
0 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-143000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1461000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-752000 usd
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-39440000 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3318000 usd
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
183000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
143000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-151000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2913000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37937000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29954000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19466000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
44000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
180000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-29998000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
19286000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73449132 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73252365 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73449132 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76247966 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
123175000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-29998000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5229000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
98406000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
104159000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
19286000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8553000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
131998000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-29998000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
19286000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1269000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
987000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1523000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
16867000 usd
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4965000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8553000 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-143000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1461000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-752000 usd
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-39440000 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3318000 usd
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
143000 usd
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 usd
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
920000 usd
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-26000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
180000 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
183000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
154000 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-14000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6141000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4660000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
993000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1332000 usd
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-189000 usd
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
42000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
24000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-456000 usd
CY2023Q1 toi Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1400000 usd
CY2022Q1 toi Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-942000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
50000 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
11000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-805000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
526000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2574000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2963000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1243000 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-909000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
316000 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15452000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16981000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1839000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1002000 usd
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
9759000 usd
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
29999000 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18401000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1002000 usd
CY2023Q1 toi Payments For Financing Of Insurance Payments
PaymentsForFinancingOfInsurancePayments
1282000 usd
CY2022Q1 toi Payments For Financing Of Insurance Payments
PaymentsForFinancingOfInsurancePayments
1235000 usd
CY2023Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
409000 usd
CY2022Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
409000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
18000 usd
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
13000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1709000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1657000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1240000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19640000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14010000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115174000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15250000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95534000 usd
CY2023Q1 toi Interest And Principal Forgiven From Paycheck Protection Program Loan Cares Act
InterestAndPrincipalForgivenFromPaycheckProtectionProgramLoanCaresAct
0 usd
CY2022Q1 toi Interest And Principal Forgiven From Paycheck Protection Program Loan Cares Act
InterestAndPrincipalForgivenFromPaycheckProtectionProgramLoanCaresAct
183000 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
68000 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1128000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
74000 usd
CY2023Q1 toi Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
3 subsidiary
CY2023Q1 toi Number Of Oncologists And Mid Level Professionals Within Three States Minimum
NumberOfOncologistsAndMidLevelProfessionalsWithinThreeStatesMinimum
98 oncologist
CY2023Q1 toi Number Of Clinic Locations
NumberOfClinicLocations
62 clinic
CY2023Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
5 state
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates under different assumptions or conditions. Significant items subject to such estimates and assumptions include judgements related to revenue recognition, estimated accounts receivable and the allowance for credit losses, useful lives and recoverability of long-lived and intangible assets, recoverability of goodwill, fair values of acquired identifiable assets and assumed liabilities in business combinations, fair value of intangible assets and goodwill, fair value of share-based compensation, fair value of liability classified instruments, and judgements related to deferred income taxes.</span></div>
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
16867000 usd
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q1 toi Accounts Receivable Allowance For Credit Loss Recovery Reversal
AccountsReceivableAllowanceForCreditLossRecoveryReversal
23000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
45956000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39816000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
11000 usd
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
177000 usd
CY2023Q1 toi Accounts Receivable Allowance For Credit Loss Recovery Reversal
AccountsReceivableAllowanceForCreditLossRecoveryReversal
10000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
76192000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55161000 usd
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
875000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1139000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
10254000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9261000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
99207000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
237000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
98973000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
121101000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
384000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
120723000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
70367000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
28606000 usd
CY2023Q1 toi Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date After Year5
DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5
0 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
98973000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
72892000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
47831000 usd
CY2022Q4 toi Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date After Year5
DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5
0 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
120723000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-143000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
7 security
CY2023Q1 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
234000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
274000 usd
CY2023Q1 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
16867000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4046000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3506000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9846000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8547000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
541000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
314000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4084000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5310000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
875000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1139000 usd
CY2023Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1728000 usd
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3010000 usd
CY2023Q1 toi Business Combination Consideration Transferred Other Current
BusinessCombinationConsiderationTransferredOtherCurrent
974000 usd
CY2022Q4 toi Business Combination Consideration Transferred Other Current
BusinessCombinationConsiderationTransferredOtherCurrent
802000 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1076000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1100000 usd
CY2023Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
3508000 usd
CY2022Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
3234000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12245000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14595000 usd
CY2023Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
1728000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1762000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1168000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
20000 usd
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
14000 usd
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3000 usd
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 usd
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
31000 usd
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
109000 usd
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
274000 usd
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
205000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5206000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
63000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6562000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
77000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5947000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
42000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5217000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
39000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4126000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0 usd
CY2023Q1 toi Lessee Operating Lease Liability To Be Paid Thereafter
LesseeOperatingLeaseLiabilityToBePaidThereafter
5181000 usd
CY2023Q1 toi Finance Lease Liability To Be Paid Thereafter
FinanceLeaseLiabilityToBePaidThereafter
29000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
32239000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
250000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4349000 usd
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
26000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
27890000 usd
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
224000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5639000 usd
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
73000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22251000 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
151000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
27890000 usd
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
224000 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M8D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M21D
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M21D
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M29D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0523
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0421
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0605
CY2022Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0439
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1581000 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1145000 usd
CY2023Q1 toi Repayments For Finance Lease
RepaymentsForFinanceLease
21000 usd
CY2022Q1 toi Repayments For Finance Lease
RepaymentsForFinanceLease
17000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1550000 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
19598000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
3000 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
40000 usd
CY2023Q1 toi Lessee Operating Lease Number Of Clinic Lease Term Extensions
LesseeOperatingLeaseNumberOfClinicLeaseTermExtensions
1 clinic
CY2023Q1 toi Operating Lease Modification Liability Increase Decrease
OperatingLeaseModificationLiabilityIncreaseDecrease
491000 usd
CY2023Q1 toi Operating Lease Modification Liability Increase Decrease Net Of Lease Incentives
OperatingLeaseModificationLiabilityIncreaseDecreaseNetOfLeaseIncentives
500000 usd
CY2023Q1 toi Operating Lease Modification Increase Decrease In Rent Expenses
OperatingLeaseModificationIncreaseDecreaseInRentExpenses
3000 usd
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
110000000 usd
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
110000000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
44000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
180000 usd
CY2023Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-136000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0015
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0092
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73754609 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73265621 shares
CY2023Q1 toi Common Stock Votes Per Share
CommonStockVotesPerShare
1 vote
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
163510 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
165045 shares
CY2023Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
100 shares
CY2023Q1 toi Preferred Stock Maximum Percent Of Common Stock Allowed
PreferredStockMaximumPercentOfCommonStockAllowed
0.049
CY2021Q4 toi Class Of Warrant Or Right Threshold Number Of Business Days Before Sending Notice Of Redemption To Warrant Holders
ClassOfWarrantOrRightThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders
3 d
CY2022Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
20000000 shares
CY2022 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
1500000 shares
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
9000000 usd
CY2022 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
5 business_combination
CY2022 toi Number Of Asset Acquired
NumberOfAssetAcquired
1 asset_acquisition
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6400
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0340
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
3724 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
281000 usd
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2198000 usd
CY2023Q1 toi Number Of Asset Acquired
NumberOfAssetAcquired
0 asset_acquisition
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 usd
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
76000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
29075000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11847000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17228000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
29075000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11118000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17957000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2184000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2913000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2909000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2884000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2757000 usd
CY2023Q1 toi Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
3581000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17228000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
728000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
673000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
4551000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
21418000 usd
CY2022Q4 us-gaap Goodwill Gross
GoodwillGross
21418000 usd
CY2021Q4 us-gaap Goodwill Gross
GoodwillGross
26626000 usd
CY2023Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 usd
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
4736000 usd
CY2023Q1 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
16867000 usd
CY2022Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
9944000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
4551000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
21418000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-29998000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
19286000 usd
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 usd
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 usd
CY2023Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-29998000 usd
CY2022Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
19286000 usd
CY2023Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
-5504000 usd
CY2022Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
3519000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24494000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
15767000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73449132 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73252365 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-29998000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
19286000 usd
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 usd
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 usd
CY2023Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Diluted
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
-29998000 usd
CY2022Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Diluted
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
19286000 usd
CY2023Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
-5504000 usd
CY2022Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
3405000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24494000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
15881000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73449132 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73252365 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2995601 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73449132 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76247966 shares
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 segment
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32867000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18471000 usd
CY2023Q1 us-gaap Assets
Assets
234633000 usd
CY2022Q4 us-gaap Assets
Assets
261665000 usd
CY2023Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
110000 usd
CY2022Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
156000 usd

Files In Submission

Name View Source Status
toi-20230331_cal.xml Edgar Link unprocessable
0001628280-23-017229-index-headers.html Edgar Link pending
0001628280-23-017229-index.html Edgar Link pending
0001628280-23-017229.txt Edgar Link pending
0001628280-23-017229-xbrl.zip Edgar Link pending
ex311-certificationrule13a.htm Edgar Link pending
ex312-certificationrule13a.htm Edgar Link pending
ex321-ceocertificationsect.htm Edgar Link pending
ex322-cfocertificationsect.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
report.css Edgar Link pending
shah-firstamendmenttoemp.htm Edgar Link pending
shah-firstamendmenttoemp001.jpg Edgar Link pending
shah-firstamendmenttoemp002.jpg Edgar Link pending
shah-firstamendmenttoemp003.jpg Edgar Link pending
shah-firstamendmenttoemp004.jpg Edgar Link pending
Show.js Edgar Link pending
toi-20230331.htm Edgar Link pending
toi-20230331.xsd Edgar Link pending
virnich-firstamendmentto.htm Edgar Link pending
virnich-firstamendmentto001.jpg Edgar Link pending
virnich-firstamendmentto002.jpg Edgar Link pending
virnich-firstamendmentto003.jpg Edgar Link pending
virnich-firstamendmentto004.jpg Edgar Link pending
toi-20230331_def.xml Edgar Link unprocessable
toi-20230331_lab.xml Edgar Link unprocessable
toi-20230331_pre.xml Edgar Link unprocessable
toi-20230331_htm.xml Edgar Link completed